20 de agosto de 2019
  • Lunes, 19 de Agosto
  • Viernes, 16 de Agosto
  • 23 de enero de 2014

    Zonegran® (zonisamide) Reimbursed in Switzerland as Monotherapy Treatment for Adults With Newly Diagnosed Partial Epilep


    - Zonegran(R) (zonisamide) as monotherapy in adults and adjunctive therapy
    in adults, adolescents and children aged six years and above with partial onset
    seizures, with or without secondary generalisation. (Zonegran is under license from
    the originator Dainippon Sumitomo Pharma)
    - Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients
    with partial onset seizures, with or without secondary generalisation. (Zebinix is
    under license from BIAL)
    - Inovelon(R) (rufinamide) for the adjunctive treatment of seizures associated
    with Lennox-Gastaut Syndrome in patients >4 years. (Rufinamide was originally
    developed by Novartis)
    - Fycompa(R) (perampanel) for use as an adjunctive treatment for partial onset
    seizures, with or without secondarily generalised seizures, in patients with epilepsy
    aged 12 years and older



    About Eisai

    Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).

    Eisai concentrates its R&D activities in three key areas:

    (CONTINUA)